Pipeline Risks Novartis faces recent DM1 and RNA-targeting therapeutic trial setbacks, signaling a potential need for enhanced data analytics, clinical trial management tools, and risk monitoring solutions to bolster program transparency and accelerate go/no-go decisions.

Board Governance Attention A major shareholder has called for a board shake-up following trial setbacks, creating an opening for governance, investor relations, and compliance services that help stabilize communications and stakeholder confidence.

Financial Levers With revenue north of ten billion and substantial funding, there is opportunity to offer cost optimization, treasury analytics, and AI-driven forecasting or scenario planning to maximize capital deployment and ROI across late-stage programs.

Global Reach Novartis serves over 250 million patients worldwide, presenting opportunities for regional market access, pharmacovigilance efficiency, and localized commercial analytics to support launches and post-market surveillance.

Digital Stack Existing tech stack including advanced analytics and AI platforms suggests a fit for expanding or upgrading capabilities in data integration, predictive analytics, and marketing tech to improve trial recruitment, patient outcomes, and stakeholder engagement.